한글목차

월경전 증후군 시장은 2023-20281년 2억 7,672만 달러, 예측 기간 중 CAGR은 3.69%로 성장할 것으로 예측됩니다.

월경전 증후군 시장의 전체적인 분석, 시장 규모·예측, 동향, 성장 촉진요인, 과제, 약 25개 벤더를 다룬 벤더 분석 등을 제공합니다.

현재의 시장 시나리오, 최신 동향과 촉진요인, 시장 환경 전체에 관한 최신 분석을 제공하고 있습니다. 시장은 PMS에 관한 인식 및 보고의 증가, 벤더간 협력 및 제휴, 허브 및 식이보충제에 대한 선호도의 증가에 의해 촉진되고 있습니다.

본 조사에서는 향후 수년간 월경전 증후군 시장의 성장을 촉진하는 주요인의 하나로 원격의료의 견고한 채택을 들고 있습니다. 또한 지역 정부에 의한 PMS 치료제 연구개발 및 월경 위생구상에 대한 고액의 투자는 시장의 큰 수요로 연결됩니다.

목차

제1장 주요 요약

• 시장 개요

제2장 시장 구도

• 시장 에코시스템

제3장 시장 규모

• 시장의 정의
• 시장 부문 분석
• 시장 규모 2023
• 시장 전망 2023-2028

제4장 시장 규모 실적

• 세계의 월경전 증후군 시장 2018-2022
• 약물 클래스 부문 분석 2018-2022
• 유통 채널 부문 분석 2018-2022
• 지역별 부문 분석 2018-2022
• 국가별 부문 분석 2018-2022

제5장 Five forces 분석

• Five Forces 요약
• 구매자의 교섭력
• 공급 기업의 교섭력
• 신규 진출업체의 위협
• 대체품의 위협
• 경쟁의 위협
• 시장 현황

제6장 시장 세분화 약제 클래스별

• 시장 부문
• 비교 약제 클래스별
• 진통제 : 시장 규모와 예측 2023-2028
• 경구 피임약 및 난소 억제제 : 시장 규모와 예측 2023-2028
• 항우울제 : 시장 규모와 예측 2023-2028
• 기타 : 시장 규모와 예측 2023-2028
• 시장 기회 약제 클래스별

제7장 시장 세분화 : 유통 채널별

• 시장 부문
• 비교 : 유통 채널별
• 소매 약국 : 시장 규모와 예측 2023-2028
• 병원 약국 : 시장 규모와 예측 2023-2028
• 온라인 약국 : 시장 규모와 예측 2023-2028
• 시장 기회 : 유통 채널별

제8장 고객 상황

• 고객 상황의 개요

제9장 지역별 상황

• 지역별 세분화
• 지역별 비교
• 북미 : 시장 규모와 예측 2023-2028
• 유럽 : 시장 규모와 예측 2023-2028
• 아시아 : 시장 규모와 예측 2023-2028
• 세계의 기타 지역 : 시장 규모와 예측 2023-2028
• 미국 : 시장 규모와 예측 2023-2028
• 독일 : 시장 규모와 예측 2023-2028
• 중국 : 시장 규모와 예측 2023-2028
• 영국 : 시장 규모와 예측 2023-2028
• 일본 : 시장 규모와 예측 2023-2028
• 시장 기회 : 지역 상황별

제10장 촉진요인, 과제 및 동향

• 시장 촉진요인
• 시장이 해결해야 할 과제
• 촉진요인과 과제의 영향
• 시장 동향

제11장 벤더 구도

• 개요
• 벤더 구도
• 혼란의 상황
• 업계의 리스크

제12장 벤더 분석

• 대상 벤더
• 벤더의 시장 포지셔닝
• AbbVie Inc.
• Bayer AG
• Eli Lilly and Co.
• GlaxoSmithKline Plc
• Herbalife International of America Inc.
• Johnson and Johnson
• Lupin Ltd.
• Merck KGaA
• Novartis AG
• Octavius Pharma Pvt. Ltd.
• Pfizer Inc.
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

제13장 부록

영문목차

The premenstrual syndrome market is forecasted to grow by USD 276.72 mn during 2023-2028, accelerating at a CAGR of 3.69% during the forecast period. The report on the premenstrual syndrome market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing awareness and reporting about PMS, collaboration and partnerships among vendors, and growing preference for herbal and dietary supplements.

Technavio's premenstrual syndrome market is segmented as below:

By Drug Class

• Analgesics
• Oral contraceptives & ovarian suppression agents
• Antidepressants
• Others

By Distribution Channel

• Retail pharmacies
• Hospital pharmacies
• Online pharmacies

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the robust adoption of telemedicine as one of the prime reasons driving the premenstrual syndrome market growth during the next few years. Also, high investment on r and d on PMS drugs and menstrual health initiatives by regional governments will lead to sizable demand in the market.

The report on the premenstrual syndrome market covers the following areas:

• Premenstrual syndrome market sizing
• Premenstrual syndrome market forecast
• Premenstrual syndrome market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading premenstrual syndrome market vendors that include AbbVie Inc., Aspen Pharmacare Holdings Ltd, Bayer AG, Bristol Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline Plc, Herbalife International of America Inc., Hikma Pharmaceuticals Plc, Johnson and Johnson, Lupin Ltd., Merck KGaA, Novartis AG, Octavius Pharma Pvt. Ltd., Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Recordati S.p.A, Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.. Also, the premenstrual syndrome market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by Drug Class
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028
• Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

• 4.1 Global premenstrual syndrome market 2018 - 2022
• Exhibit 18: Historic Market Size - Data Table on global premenstrual syndrome market 2018 - 2022 ($ million)
• 4.2 Drug Class Segment Analysis 2018 - 2022
• Exhibit 19: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million)
• 4.3 Distribution Channel Segment Analysis 2018 - 2022
• Exhibit 20: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
• 4.4 Geography Segment Analysis 2018 - 2022
• Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
• 4.5 Country Segment Analysis 2018 - 2022
• Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Drug Class

• 6.1 Market segments
• Exhibit 30: Chart on Drug Class - Market share 2023-2028 (%)
• Exhibit 31: Data Table on Drug Class - Market share 2023-2028 (%)
• 6.2 Comparison by Drug Class
• Exhibit 32: Chart on Comparison by Drug Class
• Exhibit 33: Data Table on Comparison by Drug Class
• 6.3 Analgesics - Market size and forecast 2023-2028
• Exhibit 34: Chart on Analgesics - Market size and forecast 2023-2028 ($ million)
• Exhibit 35: Data Table on Analgesics - Market size and forecast 2023-2028 ($ million)
• Exhibit 36: Chart on Analgesics - Year-over-year growth 2023-2028 (%)
• Exhibit 37: Data Table on Analgesics - Year-over-year growth 2023-2028 (%)
• 6.4 Oral contraceptives and ovarian suppression agents - Market size and forecast 2023-2028
• Exhibit 38: Chart on Oral contraceptives and ovarian suppression agents - Market size and forecast 2023-2028 ($ million)
• Exhibit 39: Data Table on Oral contraceptives and ovarian suppression agents - Market size and forecast 2023-2028 ($ million)
• Exhibit 40: Chart on Oral contraceptives and ovarian suppression agents - Year-over-year growth 2023-2028 (%)
• Exhibit 41: Data Table on Oral contraceptives and ovarian suppression agents - Year-over-year growth 2023-2028 (%)
• 6.5 Antidepressants - Market size and forecast 2023-2028
• Exhibit 42: Chart on Antidepressants - Market size and forecast 2023-2028 ($ million)
• Exhibit 43: Data Table on Antidepressants - Market size and forecast 2023-2028 ($ million)
• Exhibit 44: Chart on Antidepressants - Year-over-year growth 2023-2028 (%)
• Exhibit 45: Data Table on Antidepressants - Year-over-year growth 2023-2028 (%)
• 6.6 Others - Market size and forecast 2023-2028
• Exhibit 46: Chart on Others - Market size and forecast 2023-2028 ($ million)
• Exhibit 47: Data Table on Others - Market size and forecast 2023-2028 ($ million)
• Exhibit 48: Chart on Others - Year-over-year growth 2023-2028 (%)
• Exhibit 49: Data Table on Others - Year-over-year growth 2023-2028 (%)
• 6.7 Market opportunity by Drug Class
• Exhibit 50: Market opportunity by Drug Class ($ million)
• Exhibit 51: Data Table on Market opportunity by Drug Class ($ million)

7 Market Segmentation by Distribution Channel

• 7.1 Market segments
• Exhibit 52: Chart on Distribution Channel - Market share 2023-2028 (%)
• Exhibit 53: Data Table on Distribution Channel - Market share 2023-2028 (%)
• 7.2 Comparison by Distribution Channel
• Exhibit 54: Chart on Comparison by Distribution Channel
• Exhibit 55: Data Table on Comparison by Distribution Channel
• 7.3 Retail pharmacies - Market size and forecast 2023-2028
• Exhibit 56: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 57: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 58: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%)
• Exhibit 59: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%)
• 7.4 Hospital pharmacies - Market size and forecast 2023-2028
• Exhibit 60: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 61: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 62: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
• Exhibit 63: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%)
• 7.5 Online pharmacies - Market size and forecast 2023-2028
• Exhibit 64: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 65: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ million)
• Exhibit 66: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%)
• Exhibit 67: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%)
• 7.6 Market opportunity by Distribution Channel
• Exhibit 68: Market opportunity by Distribution Channel ($ million)
• Exhibit 69: Data Table on Market opportunity by Distribution Channel ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 71: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibit 72: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• 9.2 Geographic comparison
• Exhibit 73: Chart on Geographic comparison
• Exhibit 74: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• Exhibit 75: Chart on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 76: Data Table on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 77: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibit 78: Data Table on North America - Year-over-year growth 2023-2028 (%)
• 9.4 Europe - Market size and forecast 2023-2028
• Exhibit 79: Chart on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 80: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 81: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibit 82: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• 9.5 Asia - Market size and forecast 2023-2028
• Exhibit 83: Chart on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 84: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 85: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibit 86: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• 9.7 US - Market size and forecast 2023-2028
• Exhibit 91: Chart on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 92: Data Table on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 93: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibit 94: Data Table on US - Year-over-year growth 2023-2028 (%)
• 9.8 Germany - Market size and forecast 2023-2028
• Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• 9.9 China - Market size and forecast 2023-2028
• Exhibit 99: Chart on China - Market size and forecast 2023-2028 ($ million)
• Exhibit 100: Data Table on China - Market size and forecast 2023-2028 ($ million)
• Exhibit 101: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibit 102: Data Table on China - Year-over-year growth 2023-2028 (%)
• 9.10 UK - Market size and forecast 2023-2028
• Exhibit 103: Chart on UK - Market size and forecast 2023-2028 ($ million)
• Exhibit 104: Data Table on UK - Market size and forecast 2023-2028 ($ million)
• Exhibit 105: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibit 106: Data Table on UK - Year-over-year growth 2023-2028 (%)
• 9.11 Japan - Market size and forecast 2023-2028
• Exhibit 107: Chart on Japan - Market size and forecast 2023-2028 ($ million)
• Exhibit 108: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
• Exhibit 109: Chart on Japan - Year-over-year growth 2023-2028 (%)
• Exhibit 110: Data Table on Japan - Year-over-year growth 2023-2028 (%)
• 9.12 Market opportunity By Geographical Landscape
• Exhibit 111: Market opportunity By Geographical Landscape ($ million)
• Exhibit 112: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 113: Impact of drivers and challenges in 2023 and 2028
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 115: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 116: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 117: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 118: Matrix on vendor position and classification
• 12.3 AbbVie Inc.
• Exhibit 119: AbbVie Inc. - Overview
• Exhibit 120: AbbVie Inc. - Product / Service
• Exhibit 121: AbbVie Inc. - Key news
• Exhibit 122: AbbVie Inc. - Key offerings
• 12.4 Bayer AG
• Exhibit 123: Bayer AG - Overview
• Exhibit 124: Bayer AG - Business segments
• Exhibit 125: Bayer AG - Key news
• Exhibit 126: Bayer AG - Key offerings
• Exhibit 127: Bayer AG - Segment focus
• 12.5 Eli Lilly and Co.
• Exhibit 128: Eli Lilly and Co. - Overview
• Exhibit 129: Eli Lilly and Co. - Product / Service
• Exhibit 130: Eli Lilly and Co. - Key news
• Exhibit 131: Eli Lilly and Co. - Key offerings
• 12.6 GlaxoSmithKline Plc
• Exhibit 132: GlaxoSmithKline Plc - Overview
• Exhibit 133: GlaxoSmithKline Plc - Business segments
• Exhibit 134: GlaxoSmithKline Plc - Key news
• Exhibit 135: GlaxoSmithKline Plc - Key offerings
• Exhibit 136: GlaxoSmithKline Plc - Segment focus
• 12.7 Herbalife International of America Inc.
• Exhibit 137: Herbalife International of America Inc. - Overview
• Exhibit 138: Herbalife International of America Inc. - Product / Service
• Exhibit 139: Herbalife International of America Inc. - Key offerings
• 12.8 Johnson and Johnson
• Exhibit 140: Johnson and Johnson - Overview
• Exhibit 141: Johnson and Johnson - Business segments
• Exhibit 142: Johnson and Johnson - Key news
• Exhibit 143: Johnson and Johnson - Key offerings
• Exhibit 144: Johnson and Johnson - Segment focus
• 12.9 Lupin Ltd.
• Exhibit 145: Lupin Ltd. - Overview
• Exhibit 146: Lupin Ltd. - Product / Service
• Exhibit 147: Lupin Ltd. - Key news
• Exhibit 148: Lupin Ltd. - Key offerings
• 12.10 Merck KGaA
• Exhibit 149: Merck KGaA - Overview
• Exhibit 150: Merck KGaA - Business segments
• Exhibit 151: Merck KGaA - Key news
• Exhibit 152: Merck KGaA - Key offerings
• Exhibit 153: Merck KGaA - Segment focus
• 12.11 Novartis AG
• Exhibit 154: Novartis AG - Overview
• Exhibit 155: Novartis AG - Business segments
• Exhibit 156: Novartis AG - Key offerings
• Exhibit 157: Novartis AG - Segment focus
• 12.12 Octavius Pharma Pvt. Ltd.
• Exhibit 158: Octavius Pharma Pvt. Ltd. - Overview
• Exhibit 159: Octavius Pharma Pvt. Ltd. - Product / Service
• Exhibit 160: Octavius Pharma Pvt. Ltd. - Key offerings
• 12.13 Pfizer Inc.
• Exhibit 161: Pfizer Inc. - Overview
• Exhibit 162: Pfizer Inc. - Product / Service
• Exhibit 163: Pfizer Inc. - Key news
• Exhibit 164: Pfizer Inc. - Key offerings
• 12.14 Sanofi SA
• Exhibit 165: Sanofi SA - Overview
• Exhibit 166: Sanofi SA - Business segments
• Exhibit 167: Sanofi SA - Key news
• Exhibit 168: Sanofi SA - Key offerings
• Exhibit 169: Sanofi SA - Segment focus
• 12.15 Sun Pharmaceutical Industries Ltd.
• Exhibit 170: Sun Pharmaceutical Industries Ltd. - Overview
• Exhibit 171: Sun Pharmaceutical Industries Ltd. - Product / Service
• Exhibit 172: Sun Pharmaceutical Industries Ltd. - Key offerings
• 12.16 Teva Pharmaceutical Industries Ltd.
• Exhibit 173: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 174: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 175: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 176: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 177: Teva Pharmaceutical Industries Ltd. - Segment focus
• 12.17 Viatris Inc.
• Exhibit 178: Viatris Inc. - Overview
• Exhibit 179: Viatris Inc. - Business segments
• Exhibit 180: Viatris Inc. - Key news
• Exhibit 181: Viatris Inc. - Key offerings
• Exhibit 182: Viatris Inc. - Segment focus

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 183: Inclusions checklist
• Exhibit 184: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 185: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 186: Research methodology
• Exhibit 187: Validation techniques employed for market sizing
• Exhibit 188: Information sources
• 13.5 List of abbreviations
• Exhibit 189: List of abbreviations